Cargando…

COVID-19 Clinical Trials Registered Worldwide for Drug Intervention: An Overview and Characteristic Analysis

OBJECTIVE: This study aims to comprehensively evaluate the characteristics of clinical drug trials to facilitate the collection of evidence for COVID-19 drug treatments. METHODS: A retrospective analysis of 910 trials retrieved on August 7, 2020. RESULTS: A total of 910 registered clinical trials wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bin, Lai, Junkai, Yan, Xiaoyan, Jin, Feifei, Yi, Bin, An, Caixia, Li, Yuanxiao, Yao, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682610/
https://www.ncbi.nlm.nih.gov/pubmed/33239868
http://dx.doi.org/10.2147/DDDT.S281700
_version_ 1783612717184057344
author Wang, Bin
Lai, Junkai
Yan, Xiaoyan
Jin, Feifei
Yi, Bin
An, Caixia
Li, Yuanxiao
Yao, Chen
author_facet Wang, Bin
Lai, Junkai
Yan, Xiaoyan
Jin, Feifei
Yi, Bin
An, Caixia
Li, Yuanxiao
Yao, Chen
author_sort Wang, Bin
collection PubMed
description OBJECTIVE: This study aims to comprehensively evaluate the characteristics of clinical drug trials to facilitate the collection of evidence for COVID-19 drug treatments. METHODS: A retrospective analysis of 910 trials retrieved on August 7, 2020. RESULTS: A total of 910 registered clinical trials with at least one drug intervention were evaluated. The number of registrations (32.4%, 295) from the United States accounted for nearly one-third of the total and far exceeded that of other countries individually. Furthermore, the peak number of trials were registered in April (34.3%, 312). Over half of the trials (51.2%, 466) are in the recruitment phase, and only 4.2% (38) of the trials have been completed. The median (interquartile range) estimated enrollment is 127 (59, 365). In 39% (355) of trials, the estimated enrollment is less than 100 participants. A total of 94.5% (790) of the trials use randomization in the allocation, 82.7% (753) use a parallel intervention mode, and 52.2% (475) use masking. A total of 287 drug names have been standardized and mapped. “Hydroxychloroquine” is the leading drug among the registered trials (7.47%, 68). Among the main countries contributing to investigations on “hydroxychloroquine”, the United States ranks first with 36.76% (25) of the trials. CONCLUSION: The designs of COVID-19 clinical drug trials have greatly improved in terms of the implementation of randomization and, particularly, blinding methods. In terms of drug reuse, the number of drug types has greatly increased, and hundreds of drugs have been used for efficacy screening. The emergence of large-sample registration trials is expected to address the uncertainty regarding the current clinical efficacy of some drugs.
format Online
Article
Text
id pubmed-7682610
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-76826102020-11-24 COVID-19 Clinical Trials Registered Worldwide for Drug Intervention: An Overview and Characteristic Analysis Wang, Bin Lai, Junkai Yan, Xiaoyan Jin, Feifei Yi, Bin An, Caixia Li, Yuanxiao Yao, Chen Drug Des Devel Ther Original Research OBJECTIVE: This study aims to comprehensively evaluate the characteristics of clinical drug trials to facilitate the collection of evidence for COVID-19 drug treatments. METHODS: A retrospective analysis of 910 trials retrieved on August 7, 2020. RESULTS: A total of 910 registered clinical trials with at least one drug intervention were evaluated. The number of registrations (32.4%, 295) from the United States accounted for nearly one-third of the total and far exceeded that of other countries individually. Furthermore, the peak number of trials were registered in April (34.3%, 312). Over half of the trials (51.2%, 466) are in the recruitment phase, and only 4.2% (38) of the trials have been completed. The median (interquartile range) estimated enrollment is 127 (59, 365). In 39% (355) of trials, the estimated enrollment is less than 100 participants. A total of 94.5% (790) of the trials use randomization in the allocation, 82.7% (753) use a parallel intervention mode, and 52.2% (475) use masking. A total of 287 drug names have been standardized and mapped. “Hydroxychloroquine” is the leading drug among the registered trials (7.47%, 68). Among the main countries contributing to investigations on “hydroxychloroquine”, the United States ranks first with 36.76% (25) of the trials. CONCLUSION: The designs of COVID-19 clinical drug trials have greatly improved in terms of the implementation of randomization and, particularly, blinding methods. In terms of drug reuse, the number of drug types has greatly increased, and hundreds of drugs have been used for efficacy screening. The emergence of large-sample registration trials is expected to address the uncertainty regarding the current clinical efficacy of some drugs. Dove 2020-11-19 /pmc/articles/PMC7682610/ /pubmed/33239868 http://dx.doi.org/10.2147/DDDT.S281700 Text en © 2020 Wang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wang, Bin
Lai, Junkai
Yan, Xiaoyan
Jin, Feifei
Yi, Bin
An, Caixia
Li, Yuanxiao
Yao, Chen
COVID-19 Clinical Trials Registered Worldwide for Drug Intervention: An Overview and Characteristic Analysis
title COVID-19 Clinical Trials Registered Worldwide for Drug Intervention: An Overview and Characteristic Analysis
title_full COVID-19 Clinical Trials Registered Worldwide for Drug Intervention: An Overview and Characteristic Analysis
title_fullStr COVID-19 Clinical Trials Registered Worldwide for Drug Intervention: An Overview and Characteristic Analysis
title_full_unstemmed COVID-19 Clinical Trials Registered Worldwide for Drug Intervention: An Overview and Characteristic Analysis
title_short COVID-19 Clinical Trials Registered Worldwide for Drug Intervention: An Overview and Characteristic Analysis
title_sort covid-19 clinical trials registered worldwide for drug intervention: an overview and characteristic analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682610/
https://www.ncbi.nlm.nih.gov/pubmed/33239868
http://dx.doi.org/10.2147/DDDT.S281700
work_keys_str_mv AT wangbin covid19clinicaltrialsregisteredworldwidefordruginterventionanoverviewandcharacteristicanalysis
AT laijunkai covid19clinicaltrialsregisteredworldwidefordruginterventionanoverviewandcharacteristicanalysis
AT yanxiaoyan covid19clinicaltrialsregisteredworldwidefordruginterventionanoverviewandcharacteristicanalysis
AT jinfeifei covid19clinicaltrialsregisteredworldwidefordruginterventionanoverviewandcharacteristicanalysis
AT yibin covid19clinicaltrialsregisteredworldwidefordruginterventionanoverviewandcharacteristicanalysis
AT ancaixia covid19clinicaltrialsregisteredworldwidefordruginterventionanoverviewandcharacteristicanalysis
AT liyuanxiao covid19clinicaltrialsregisteredworldwidefordruginterventionanoverviewandcharacteristicanalysis
AT yaochen covid19clinicaltrialsregisteredworldwidefordruginterventionanoverviewandcharacteristicanalysis